Trial Profile
An Open-Label Adaptive Study for the Assessment of Safety, Tolerability, Pharmacokinetics, and Efficacy of Multiple Doses of Radiprodil in Subjects With Drug-Resistant Infantile Spasms
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 30 Jul 2020
Price :
$35
*
At a glance
- Drugs Radiprodil (Primary)
- Indications Infantile spasms
- Focus Adverse reactions; Therapeutic Use
- Sponsors UCB Biopharma
- 31 Oct 2018 Status changed from recruiting to discontinued after reviewing the feasibility and projected completion date of the study, UCB has made the decision to stop the study
- 09 Apr 2018 Planned End Date changed from 11 Nov 2020 to 19 Mar 2021.
- 09 Apr 2018 Planned primary completion date changed from 11 Nov 2020 to 19 Mar 2021.